Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

Niels Heersche; Daan A. C. Lanser; Esther Oomen-de Hoop; Attila Içli; Peter de Bruijn; Marthe S. Paats; Elisabeth F. C. van Rossum; Stijn L. W. Koolen; Ron H. N. van Schaik; Anne-Marie C. Dingemans; G. D. Marijn Veerman; Ron H. J. Mathijssen

doi:10.1002/cac2.70030

Cancer Communications ›› 2025, Vol. 45 ›› Issue (8) : 914 -918. DOI: 10.1002/cac2.70030

LETTER TO THE JOURNAL

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

Author information +

History +

PDF

Cite this article

Download citation ▾

Niels Heersche, Daan A. C. Lanser, Esther Oomen-de Hoop, Attila Içli, Peter de Bruijn, Marthe S. Paats, Elisabeth F. C. van Rossum, Stijn L. W. Koolen, Ron H. N. van Schaik, Anne-Marie C. Dingemans, G. D. Marijn Veerman, Ron H. J. Mathijssen. Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study. Cancer Communications, 2025, 45(8): 914-918 DOI:10.1002/cac2.70030

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4): 339–57.

[2]	Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024; 390(14): 1265–76.

[3]	de Leeuw SP, Pruis MA, Sikkema BJ, Mohseni M, Veerman GDM, Paats MS, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer. J Thorac Oncol. 2023; 18(8): 1017–30.

[4]	Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols A, Mathijssen RHJ, et al. Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials. J Clin Oncol. 2025; 43(6): 641–50.

[5]	Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024; 75: 102782.

[6]	Lee ATM, Ou SI, Lisberg A. Letter to Editor. Re “de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer,” Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors? J Thorac Oncol. 2023; 18(9): e97–e9.

[7]	Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, et al. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2021; 109(2): 394–402.

[8]	Lanser DAC, de Leeuw SP, Oomen-de Hoop E, de Bruijn P, Paats MS, Dumoulin DW, et al. Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial. J Natl Compr Canc Netw. 2023; 21(6): 645–51 e1.

[9]

Hsu JC, Jaminion F, Guerini E, Balas B, Bordogna W, Morcos PN, et al. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. CPT Pharmacometrics Syst Pharmacol. 2021; 10(11): 1357–70.

[10]	Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19(9): 1242–51.